Longitudinal Study of 1H MRS of Lactate Upon Treatment in a Non-Hodgkins Lymphoma Patient

Seung -Cheol Lee¹, Eric A. Mellon¹, Harish Poptani¹, Edward James Delikatny¹, Jerry David Glickson¹

Previously weve shown in a human lymphoma xenograft model that in vivo MRS detected lactate is a very early marker of response to either CHOP or R-CHOP therapy. Last year weve presented clinical scanner version of the lactate detection sequence (Hadamard-SelMQC-CSI) in the phantom studies. This year we applied the clinical scanner version of the lactate sequence to monitoring early response to R-CHOP therapy in a non-Hodgkins lymphoma patient.